Glucocorticoids antagonize insulin’s antiproteolytic action on skeletal muscle in humans

Rita Jean Louard, Rajat Bhushan, Robert A. Gelfand, Eugene J. Barrett, Robert S. Sherwin

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Although chronic glucocorticoid elevations cause net skeletal muscle protein loss in man, the kinetic mechanisms responsible for this catabolic effect and the capacity of insulin to overcome it remain unclear. To examine this issue, we measured basal and insulin-stimulated rates of protein synthesis and breakdown in muscle using the phenylalanine forearm kinetic method in eight normal volunteers studied postabsorptively and after 4 days of dexamethasone treatment (8 mg/day). To avoid the confounding effects of systemic insulinization, local forearm insulin levels were raised by approximately 430 pmol/L using a 150-min brachial arterial infusion of insulin (0.251 pmol/kg.min). Postabsorptively, dexamethasone produced mild hyperglycemia (P < 0.003) and a 3-fold rise in plasma insulin (P < 0.001), but no change in forearm phenylalanine balance or kinetics. Before dexamethasone treatment, local hyperinsulinemia increased forearm glucose uptake 2.5-fold and caused a positive net balance of phenylalanine due to a marked 40% inhibition of proteolysis. After dexamethasone treatment, forearm glucose uptake was modestly reduced. However, forearm net phenylalanine balance remained negative due to a striking reduction in insulin’s inhibitory effect on proteolysis. We conclude that 1) the effects of glucocorticoid on basal muscle protein turnover are minimized by compensatory hyperinsulinemia, and 2) glucocorticoids cause muscle resistance to insulin's antiproteolytic action.

Original languageEnglish (US)
Pages (from-to)278-284
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume79
Issue number1
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Insulins
Forearm
Glucocorticoids
Muscle
Skeletal Muscle
Phenylalanine
Dexamethasone
Insulin
Proteolysis
Muscle Proteins
Hyperinsulinism
Kinetics
Enzyme inhibition
Glucose
Muscles
Hyperglycemia
Insulin Resistance
Healthy Volunteers
Arm
Plasmas

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Glucocorticoids antagonize insulin’s antiproteolytic action on skeletal muscle in humans. / Louard, Rita Jean; Bhushan, Rajat; Gelfand, Robert A.; Barrett, Eugene J.; Sherwin, Robert S.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 79, No. 1, 1994, p. 278-284.

Research output: Contribution to journalArticle

Louard, Rita Jean ; Bhushan, Rajat ; Gelfand, Robert A. ; Barrett, Eugene J. ; Sherwin, Robert S. / Glucocorticoids antagonize insulin’s antiproteolytic action on skeletal muscle in humans. In: Journal of Clinical Endocrinology and Metabolism. 1994 ; Vol. 79, No. 1. pp. 278-284.
@article{8eaa34946b1a4a21a4e28949962d147c,
title = "Glucocorticoids antagonize insulin’s antiproteolytic action on skeletal muscle in humans",
abstract = "Although chronic glucocorticoid elevations cause net skeletal muscle protein loss in man, the kinetic mechanisms responsible for this catabolic effect and the capacity of insulin to overcome it remain unclear. To examine this issue, we measured basal and insulin-stimulated rates of protein synthesis and breakdown in muscle using the phenylalanine forearm kinetic method in eight normal volunteers studied postabsorptively and after 4 days of dexamethasone treatment (8 mg/day). To avoid the confounding effects of systemic insulinization, local forearm insulin levels were raised by approximately 430 pmol/L using a 150-min brachial arterial infusion of insulin (0.251 pmol/kg.min). Postabsorptively, dexamethasone produced mild hyperglycemia (P < 0.003) and a 3-fold rise in plasma insulin (P < 0.001), but no change in forearm phenylalanine balance or kinetics. Before dexamethasone treatment, local hyperinsulinemia increased forearm glucose uptake 2.5-fold and caused a positive net balance of phenylalanine due to a marked 40{\%} inhibition of proteolysis. After dexamethasone treatment, forearm glucose uptake was modestly reduced. However, forearm net phenylalanine balance remained negative due to a striking reduction in insulin’s inhibitory effect on proteolysis. We conclude that 1) the effects of glucocorticoid on basal muscle protein turnover are minimized by compensatory hyperinsulinemia, and 2) glucocorticoids cause muscle resistance to insulin's antiproteolytic action.",
author = "Louard, {Rita Jean} and Rajat Bhushan and Gelfand, {Robert A.} and Barrett, {Eugene J.} and Sherwin, {Robert S.}",
year = "1994",
doi = "10.1210/jcem.79.1.8027242",
language = "English (US)",
volume = "79",
pages = "278--284",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Glucocorticoids antagonize insulin’s antiproteolytic action on skeletal muscle in humans

AU - Louard, Rita Jean

AU - Bhushan, Rajat

AU - Gelfand, Robert A.

AU - Barrett, Eugene J.

AU - Sherwin, Robert S.

PY - 1994

Y1 - 1994

N2 - Although chronic glucocorticoid elevations cause net skeletal muscle protein loss in man, the kinetic mechanisms responsible for this catabolic effect and the capacity of insulin to overcome it remain unclear. To examine this issue, we measured basal and insulin-stimulated rates of protein synthesis and breakdown in muscle using the phenylalanine forearm kinetic method in eight normal volunteers studied postabsorptively and after 4 days of dexamethasone treatment (8 mg/day). To avoid the confounding effects of systemic insulinization, local forearm insulin levels were raised by approximately 430 pmol/L using a 150-min brachial arterial infusion of insulin (0.251 pmol/kg.min). Postabsorptively, dexamethasone produced mild hyperglycemia (P < 0.003) and a 3-fold rise in plasma insulin (P < 0.001), but no change in forearm phenylalanine balance or kinetics. Before dexamethasone treatment, local hyperinsulinemia increased forearm glucose uptake 2.5-fold and caused a positive net balance of phenylalanine due to a marked 40% inhibition of proteolysis. After dexamethasone treatment, forearm glucose uptake was modestly reduced. However, forearm net phenylalanine balance remained negative due to a striking reduction in insulin’s inhibitory effect on proteolysis. We conclude that 1) the effects of glucocorticoid on basal muscle protein turnover are minimized by compensatory hyperinsulinemia, and 2) glucocorticoids cause muscle resistance to insulin's antiproteolytic action.

AB - Although chronic glucocorticoid elevations cause net skeletal muscle protein loss in man, the kinetic mechanisms responsible for this catabolic effect and the capacity of insulin to overcome it remain unclear. To examine this issue, we measured basal and insulin-stimulated rates of protein synthesis and breakdown in muscle using the phenylalanine forearm kinetic method in eight normal volunteers studied postabsorptively and after 4 days of dexamethasone treatment (8 mg/day). To avoid the confounding effects of systemic insulinization, local forearm insulin levels were raised by approximately 430 pmol/L using a 150-min brachial arterial infusion of insulin (0.251 pmol/kg.min). Postabsorptively, dexamethasone produced mild hyperglycemia (P < 0.003) and a 3-fold rise in plasma insulin (P < 0.001), but no change in forearm phenylalanine balance or kinetics. Before dexamethasone treatment, local hyperinsulinemia increased forearm glucose uptake 2.5-fold and caused a positive net balance of phenylalanine due to a marked 40% inhibition of proteolysis. After dexamethasone treatment, forearm glucose uptake was modestly reduced. However, forearm net phenylalanine balance remained negative due to a striking reduction in insulin’s inhibitory effect on proteolysis. We conclude that 1) the effects of glucocorticoid on basal muscle protein turnover are minimized by compensatory hyperinsulinemia, and 2) glucocorticoids cause muscle resistance to insulin's antiproteolytic action.

UR - http://www.scopus.com/inward/record.url?scp=84995826599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995826599&partnerID=8YFLogxK

U2 - 10.1210/jcem.79.1.8027242

DO - 10.1210/jcem.79.1.8027242

M3 - Article

C2 - 8027242

AN - SCOPUS:84995826599

VL - 79

SP - 278

EP - 284

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 1

ER -